Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies
NCT05232630Phase 4Completed
- Sponsor
- Hospital Ruber Internacional
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fenfluramine in Developmental and Epileptic Encephalopathies (DEE), epilepsy, SYNGAP1-related developmental and epileptic encephalopathy (SYNGAP1-DEE) and 3 more (4 arms), sponsored by Hospital Ruber Internacional. Primary endpoint: Seizure frequency at 12 months. Started Oct 2022; status: completed.
02
Drugs
fenfluramine
03
Conditions
Developmental and Epileptic Encephalopathies (DEE)epilepsySYNGAP1-related developmental and epileptic encephalopathy (SYNGAP1-DEE)STXBP1 encephalopathy (STXBP1E)inv dup(15) encephalopathy
Beyond the preview
Go deeper on NCT05232630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232630.